CKD

Three research scientists, including a nephrologist, awarded Nobel Prize in Medicine for work with how cells sense and adapt to oxygen

Announced on October 7th, the Nobel Prize in Medicine was jointly awarded to a trio of scientists, William G. Kaelin Jr., Peter J. Ratcliffe, and Gregg L. Semenza, for their work on “how cells sense and adapt to oxygen availability,” The New York Times reports.

These “investigators uncovered detailed genetic responses to changing oxygen levels that allow cells in the bodies of humans and other animals sense and respond to fluctuations, increasing and decreasing how much oxygen they receive.”

Washington Post Opinion Piece Highlights Bipartisan Agreement on Opportunities for Improvement in Organ Procurement

In a Friday, October 4, Washington Post opinion piece, former White House Office of Science and Technology Policy staffer Jennifer Erickson calls for a reform of the current United States organ procurement system.

KidneyX award recipient receives HHS contract to provide hemodialysis systems for disaster response

The U.S. Department of Health and Human Services (HHS) has awarded a contract to a KidneyX award winner to provide hemodialysis systems in communities hit by natural disasters. The HHS Office of the Assistant Secretary for Preparedness and Response has stated it will be prepared to use the systems by the end of this year.

JASN Editor in Chief Josie Briggs, MD, Appointed Interim Executive Director of PCORI

On September 27th, the Patient-Centered Outcomes Research Institute (PCORI) announced the appointment of Josephine P. Briggs, MD, as PCORI’s Interim Executive Director, starting on November 1, 2019. Briggs will lead the organization during its search for a replacement for Joe Selby, MD, MPH, who announced plans to retire as Executive Director by year’s end. She will continue her work as JASN Editor-in-Chief during this time.

FDA approves first new treatment in 20 years to treat diabetic kidney disease and reduce the risk of hospitalization for heart failure

The U.S. FDA has now approved INVOKANA® (canagliflozin) as the only type 2 diabetes (T2D) medicine indicated to treat diabetic kidney disease (DKD) and reduce the risk of hospitalization for heart failure in patients with T2D and DKD.  Approximately 1 in 3 patients with T2D also has DKD, which can ultimately lead to kidney failure. Once patients reach kidney failure, the average 5-year survival is less than 40%, largely due to cardiovascular-associated morbidity and mortality.

KHI Technology Roadmap for Innovative Approaches to Kidney Replacement Therapies

With the aid of patients, care partners, and multiple academic, private, and public communities, the Kidney Health Initiative’s newly developed technology roadmap is catalyzing innovative approaches to kidney replacement therapy (KRT). The roadmap provides guidance for innovators and entrepreneurs who are working to redesign dialysis and provide better care for those with kidney disease.

Medicare Makes Bold Move to Increase Access to Transplants

In a bold move to increase organ transplantation, the Centers for Medicare and Medicaid Services (CMS or Medicare) has finalized a proposal “to remove the requirements at § 482.82 (conditions of participation for transplant centers) that require transplant centers to submit clinical experience, outcomes, and other data in order to obtain Medicare re-approval.” The American Society of Nephrology (ASN) and other members of the kidney community advocated for this change to reduce the unintended consequences associated with the re-approval process.

ASN Weighs in on ESRD Treatment Choice Model in Letter to CMS

Reducing the benchmark for the combined home dialysis and transplant rate and allowing for incremental achievement of the benchmark, incentivizing and investing wisely to ensure needed practice transformation, and delaying the start date of the ESRD Treatment Choice Model (ETC) until April 2020 are among the recommendations for adjustments to the model set forth in a letter sent to CMS Administrator Seema Verma on behalf of ASN and its members from President Mark E. Rosenberg, MD, FASN.

New NephSAP Issue - "Chronic Kidney Disease and Progression"

NephSAP Volume 18, Number 4, September 2019

Chronic Kidney Disease and Progression

Interview with Dr. Michael Allon, editor-in-chief of Kidney360, on new ideas for the journal

allon-michael2_1.jpgKidney News Online (KNO) recently spoke with Michael Allon, MD, the inaugural Editor-in-Chief for the newest journal from the American Society of Nephrology, Kidney360. As the open access, online only journal began accepting manuscripts on October 1st, KNO wanted to learn more about the ideas behind the new journal.

 

Pages